PMID- 16261401
OWN - NLM
STAT- MEDLINE
DCOM- 20070116
LR  - 20060213
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 95
IP  - 1
DP  - 2006 Jan
TI  - A French national survey on infiltrating breast cancer: analysis of 
      clinico-pathological features and treatment modalities in 1159 patients.
PG  - 55-64
AB  - BACKGROUND: Despite the approximate 42,000 yearly new cases of breast cancer in 
      France, there have been very few exhaustive studies on the clinicopathological 
      features and treatment options of this disease. METHODS: Thus, a prospective, 
      non-selective, nationwide survey on infiltrating breast cancer (IBC) was 
      conducted in France from September 2001 to April 2002, in order to assess the 
      epidemiological features of newly diagnosed disease, the prognostic and 
      predictive variables with a special emphasis on hormone receptors, and the 
      current approaches to therapy in everyday clinical practice. RESULTS: In total, 
      1159 patients were evaluable (median age 57 years); two-thirds of women were 
      postmenopausal and 38% had undergone hormonal replacement therapy (HRT). Ductal 
      and lobular infiltrating cancers represented 82.3% and 11.6% of cases, 
      respectively. Most tumours expressed oestrogen (79.7%) and progesterone (69.7%) 
      receptors. Overexpression of the human epidermal growth factor receptor-2 
      oncogene was found in 20.6% of the assessed cases. IBC diagnosed in women under 
      HRT presented significantly better clinico-pathological features than in 
      non-users. All patients underwent surgery as first treatment: 77.5% 
      breast-conserving surgery (BCS) and 22.5% mastectomy; 1024 patients also 
      underwent axillary surgery. The overall axillary lymph-node involvement rate was 
      44.4%. Radiotherapy was proposed in 98% and 83% of the women who had undergone 
      BCS and mastectomy, respectively. Adjuvant chemotherapy was delivered in 58.7% of 
      patients and hormonal treatment was provided in 76.5% of patients; tamoxifen was 
      the most widely used hormonal treatment. CONCLUSIONS: This study showed a trend 
      for global downstaging of IBC (with favourable clinico-pathological features), 
      leading to a high rate of BCS. Postoperative treatments were widely used, in 
      accordance with national and international guidelines. Use of aromatase 
      inhibitors and taxanes was limited, but is likely to rise in the future.
FAU - Cutuli, Bruno
AU  - Cutuli B
AD  - Department of Oncology and Radiotherapy, Polyclinique de Courlancy, Reims, 
      France. b.cutuli@wanadoo.fr
FAU - Cottu, Paul Henri
AU  - Cottu PH
FAU - Guastalla, Jean Paul
AU  - Guastalla JP
FAU - Mechin, Hubert
AU  - Mechin H
FAU - Costa, Anne
AU  - Costa A
FAU - Jourdan, Rosemary
AU  - Jourdan R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20051027
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*epidemiology/pathology/therapy
MH  - Carcinoma, Ductal, Breast/epidemiology/pathology/therapy
MH  - Carcinoma, Lobular/epidemiology/pathology/therapy
MH  - Chemotherapy, Adjuvant
MH  - Combined Modality Therapy
MH  - Estrogen Replacement Therapy
MH  - Female
MH  - France/epidemiology
MH  - *Health Surveys
MH  - Humans
MH  - Mastectomy
MH  - Menopause
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Survival Rate
EDAT- 2005/11/02 09:00
MHDA- 2007/01/17 09:00
CRDT- 2005/11/02 09:00
PHST- 2005/07/08 00:00 [received]
PHST- 2005/07/19 00:00 [accepted]
PHST- 2005/11/02 09:00 [pubmed]
PHST- 2007/01/17 09:00 [medline]
PHST- 2005/11/02 09:00 [entrez]
AID - 10.1007/s10549-005-9034-6 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2006 Jan;95(1):55-64. doi: 10.1007/s10549-005-9034-6. 
      Epub 2005 Oct 27.